Page 2 - ஸ்க்லரோசிஸ் சங்கம் ஆஃப் அமெரிக்கா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1 The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod s efficacy and safety 1,2,3 Approval builds on Janssen s deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS Janssen, the Pharmaceutical Companies of Johnson Johnson, announced today that the European Commission (EC) has approved PONVORY ? (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

United statesAlexandra nisipeanuGavin giovannoniJennifer mcintyrePrinzj ponesimodChris deloreficeNone of the janssen pharmaceutical companiesEuropean commissionAmericas committee for treatmentSclerosis association of americaNational multiple sclerosis societyJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonActelion pharmaceuticals ltdExchange commission